Family seeks help as ailing father awaits transplant

2008-08-31 14:10:05

Family seeks help as ailing father awaits transplant
John Oxford
MOULTRIE - In order for Joseph Barrett to stay alive, he will need a liver
transplant in the near future. In order for his family to visit him and get
through each day, they will need help from the community.
Barrett, 41, said he and his family moved to Moultrie in 2004 to be closer to
his disabled brother, who lives in Pavo. After moving here, however, he
discovered that he was sick.
Barrett was given a blood transfusion after an automobile accident when he was
20. Because of that transfusion, he was diagnosed with hepatitis-C in 2005, and
it has wreaked havoc on his liver and caused pancreatits.
"If he doesn't get this liver transplant," Barrett's wife, Tammy, said, "he
won't be here another year. I'm scared to death of losing him."
The family has been in contact with Emory Healthcare in Atlanta, and Barrett
said he will be going to a consultation meeting in May to begin the process to
get a new liver.
Barrett said he will be in the hospital in Atlanta for six months to receive the
organ and recover from the surgery. His insurance will be able to cover most, if
not all, of the costs for the transplant, he said, but the family is asking the
community for help for their everyday costs during his recovery.
The family's four children, Allison, 14, Andrew, 12, Kayla, 9, and Faith Ann, 6,
began asking neighbors and businesses for help with their expenses, Barrett
said. The kids were able to raise $142 in a couple a days, and a couple of
businesses have pledged support to the family.
Tammy Barrett said the family will need financial help for lodging while he is
at Emory, a rental car and car money and everyday expenses. They currently have
to rent a refrigerator and stove and are without a dryer and reliable
transportation.
Any help that can be given to the family will be greatly appreciated, Tammy
Barrett said. Joseph Barrett said he wants to be able to live a long life and
see his kids grown up.
"I just want to see my kids walk down the aisle," Joseph said.
Anyone who would like to support the family can contact them at (229) 200-6737
or at 600 12th Ave. S.E.
http://www.moultrieobserver.com/local/local_story_096224743.html?keyword=topstor\
y

Individualization of Treatment Duration in Genotype 1 HCV-Positive Patients

2008-08-31 09:55:07

Summary and Comment
Individualization of Treatment Duration in Genotype 1 HCV-Positive Patients
Is it time to stop treating all HCV-positive patients the same way?
Currently, patients who are infected with genotype 1 hepatitis C virus (HCV)
receive 48 weeks of peginterferon plus ribavirin therapy, which results in
sustained virologic responses (SVRs) in about 45%. Therapy is expensive and is
associated with substantial side effects. Using a patient's initial time to
virologic response as an indicator for individualizing therapy duration could
permit shorter, but effective, exposures. In this study, researchers in Italy
evaluated the efficacy of individualized peginterferon plus ribavirin therapy in
696 genotype 1 HCV-positive patients.
In a 1:2 ratio, HCV-positive patients with well-compensated disease were
randomized to receive peginterferon plus weight-based ribavirin (standard doses)
for 48 weeks or to undergo an individualized program, in which duration of
therapy was based on the time (during the first 12 weeks of treatment) when HCV
first became undetectable. If virus was first undetectable at week 4, 8, or 12,
patients in the individualized group received therapy for a total of 24, 48, or
72 weeks; if a 2 log drop occurred by week 12 but the patient still had
detectable virus, treatment continued for 72 weeks. Patients in either group
with <2 log drop at week 12 were considered nonresponders and were removed from
the study. In both groups, dose reductions and growth factors were employed to
combat cytopenias. The primary endpoint was SVR. This study was designed as a
noninferiority analysis (assuming that standard therapy would result in SVR of
45% and that the individualized group would be within 5%).
SVR rates were not significantly different in the two groups (standard, 45%, and
individualized, 49%; P=0.37). Overall, the percentages of patients who first
achieved undetectable viral counts at weeks 4, 8, or 12 were 26.6%, 27.2%, and
10.5%, respectively, and did not differ significantly by treatment arm, except
in the subgroup of patients who did not respond until 12 weeks, in which the SVR
rate was 64% in the individualized group and 38% in the standard group. Relapse
rates and discontinuation rates were similar between the groups.
Comment: SVR rates were similar in genotype 1 HCV-positive patients who were
treated either for the standard 48 weeks or for individualized durations. Some
patients (those with undetectable viral counts at week 4) probably were
overtreated, and some (those with only a 2 log drop at week 12) probably were
undertreated. However, based on the data, the main beneficiaries of
individualized therapy were patients who were late responders and received
extended therapy. These data do raise concerns about shortening durations of
therapy in genotype 1 HCV-positive patients.
- Atif Zaman, MD, MPH
Published in Journal Watch Gastroenterology April 4, 2008
Citation(s):
Mangia A et al. Individualized treatment duration for hepatitis C genotype 1
patients: A randomized controlled trial. Hepatology 2008 Jan; 47:43.
Medline abstract (Free)

'Bad blood' victims brace for fresh battle against lawyers

2008-08-31 08:40:01

'Bad blood' victims brace for fresh battle against lawyers
Victims infected with hepatitis C in the bad blood scandal of the 1990s are
facing a fresh battle against their lawyers.
The lawyers are claiming thousands of dollars in legal costs from compensation
awarded by the state.
The dispute is preventing 25 victims with haemophilia from receiving lump sums
from the Government and delaying some members from starting treatment for the
hepatitis C they contracted through contaminated blood products. Brian O'Mahony,
the head of the Irish Haemophilia Society, who visited Christchurch this week,
has called the latest twist in the saga "grotesque", "bizarre" and
"unprecedented". He is calling for a truce so victims can get their long-awaited
compensation.
In December 2006, the Government announced a $31 million package for people
infected with hepatitis from blood products before screening was belatedly
introduced in New Zealand in 1992.
About 180 people with haemophilia and nearly 400 others were infected by then,
despite screening becoming commercially available overseas in 1990.
So far, 486 victims have applied for one-off payments and the Government has
paid out $25.5m.
Most of the affected haemophiliacs -- about 155 -- have received packages from
$43,200 to $69,600, enabling many to start a chemotherapy-type drug course for
hepatitis C. The liver-attacking virus can lead to cirrhosis (scarring) and
cancer.
But the 25 victims, including two from Christchurch, have held off accepting
compensation while they are locked in a dispute with their lawyers, who are
seeking costs of $12,700 to $18,500 per person, ranging from 19 per cent to 38%
of the packages.
The victims were among 55 haemophiliacs, and 215 clients in total, who signed up
for a class action to sue the Government for failing to introduce national
screening earlier.
The action never went ahead because a political settlement was reached after 14
years of negotiation between the Haemophilia Foundation of New Zealand and
successive governments.
But the lawyers, Johnston Lawrence, of Wellington and Penney Patel Law, of
Auckland, still want the cut that was agreed when the civil suit was being
planned. Thirty haemophiliac clients have settled, many because they needed the
money to start up to 48 weeks of hepatitis C treatment with crippling side
effects which could render them unable to work. The rest are holding out in the
hope agreement can be reached. For Mike Mapperson, one of those waiting to
settle, it is a matter of principle.
Of the $39,000, plus $2000 legal fees, he is entitled to, the lawyers want a
third. "I signed up with the lawyers on the basis that there was going to be a
legally achieved settlement. But I don't think the lawyers actually achieved the
settlement. The Haemophilia Foundation did."
"The contract never had any clauses in it to say that if there's a political
settlement, rather than a legal settlement, you won't have to pay any fees or as
many fees.
"The benefit -- or the disadvantage -- of hindsight now shows that the lawyers
get paid no matter how we get the money and no matter how much money we get."
So far, despite 14 months of negotiation between the foundation and lawyers, the
dispute remains unresolved. More lawyers for both sides, and more costs, will be
involved in trying to settle the row through mediation in Wellington next month.
Roger Chapman, a senior partner of Johnston Lawrence who is handling the bad
blood matter, is overseas until the end of the month. His firm said only Chapman
could respond to the issue.
Norman Elliot, a principal of Penney Patel Law did not want to comment.
O'Mahony, a past president of the World Federation of Haemophilia, said the fact
that some people were having to put their treatment on hold, because the dispute
had delayed settlement, was "grotesque, unbelievable, bizarre and it is
unprecedented".
In Ireland, where a political settlement reached in 1991 for haemophiliacs who
contracted HIV resulted in the winding up of a class action, lawyers were paid
3% of each victim's award.
"Here they are looking for 19% to 38%," O'Mahony said. "It's unconscionable."
Claimants should not have to pay large fees to the lawyers for the work carried
out by the Haemophilia Foundation, he said.
O'Mahony is urging lawyers to reach an agreement with victims to bring some
closure.
Mapperson said that, unlike other cases, the dispute was not delaying his access
to treatment.
http://www.stuff.co.nz:80/4467019a11.html

Reminder for Tallahassee Support Group

2008-08-30 22:06:54

Tallahassee Hepatitis Support Group (all liver diseases welcome!)
Monday April 7, 2008
7:00 to 9:00 PM
First Monday of every month
TMH Diabetes Clinic
1981 Capital Circle Northeast
Tallahassee Florida
Phone: 850-443-8029
You can contact Susan at Susan.cason@... or Pam at figment@...

Total Eclipse Of The Heart

2008-08-30 20:52:15

Total Eclipse Of The Heart
http://www.youtube.com/watch?v=1f_6aazCgGA

Hepatitis Awareness Day letter writing campaign

2008-08-30 16:52:54

Hepatitis C Advocates United is having a Hepatitis Awareness Day letter writing
campaign
Please go to www.congress.org to find out who your representatives are. Don't
forget that May 19th is World Hepatitis Day! Please post this on Hepatitis C
Bulletin Boards and pass it to everyone they know and please ask them to do the
same. There will be a national *call in* on that day so please mark you
calendars.

Frank/AntiqueHippy is not doing well :-(

2008-08-30 11:24:23

I received this earlier today and I know that many of you on a lot of these

Hepatitis crisis not on Congress' radar

2008-08-30 04:34:50

Hepatitis crisis not on Congress' radar
Little interest shown despite CDC warnings of broad implications
By STEVE TETREAULT
STEPHENS WASHINGTON BUREAU
WASHINGTON -- The health crisis created by unsafe practices documented at the
Endoscopy Clinic of Southern Nevada has commanded public attention in Las Vegas.
But as far as grabbing the lapels of Congress, that is quite another thing.
More than a month after warnings went out to 40,000 patients to be tested for
HIV and hepatitis strains, Nevada lawmakers are trying to persuade colleagues to
take note of the largest notification of its kind in U.S. history.
But efforts to interest House and Senate committees to sponsor hearings on the
episode in the context of others where questionable activities by doctors led to
disease outbreaks have yielded no fruit so far.
If anything, the inquiries have raised questions as to whether Congress should
have any investigations role at all in the matter, several lawmakers said
Wednesday.
Rep. Shelley Berkley, D-Nev., has discussed hearings with Rep. Frank Pallone,
D-N.J., House health subcommittee chairman, and has written to investigations
chairman Rep. Bart Stupak, D-Mich.
Berkley said she is awaiting a decision from Pallone. But the chairman has asked
some surprising questions.
"Is this situation particular to Southern Nevada? It was particularly egregious
and we all agree about that but does it have national implications? Does this
happen in other clinics across the country, and how much authority does Congress
have in regulating these issues?" Berkley said. "That is the gentleman's
question.
"When I spoke to (Pallone) initially, he said this was an issue he tried to move
forward a few years ago and he got zero interest," Berkley said. "He wanted to
know why now would there be more interest in Congress."
Sen. John Ensign, R-Nev., said he has received the same reception in the Senate.
"They think it is a Nevada problem," Ensign said.
Ensign did not say who told him that. He declined through his staff to
elaborate, and a spokesman said he was still working on it.
"We hope it is not a national problem, and that is why there has been some
pushback," said Sen. Harry Reid, the Senate majority leader. "Until there is
more evidence this is a national problem, I don't think you are going to have a
lot of members of Congress diving into this."
So far, seven cases of hepatitis C have been traced to practices at the
Endoscopy Center's Shadow Lane clinic and other ambulatory surgical centers
operated by Dr. Dipak Desai.
Among unsafe practices, investigators found personnel were reusing syringes and
were using single-use vials of anesthesia medication on multiple patients.
The Centers for Disease Control and Prevention, which has been assisting state,
local and federal authorities, considers the Las Vegas clinic practices an issue
with broad implications, spokeswoman Christine Pearson said, citing comments by
the agency's director, Dr. Julie Gerberding.
In a March 3 telephone call with reporters, Gerberding said the hepatitis C
outbreak in Las Vegas may be just a glimpse of safety problems around the
country.
"Unfortunately we have seen other large-scale situations where similar practices
have led to patient exposures," Gerberding said. "Our concern is that this could
represent the tip of an iceberg and we need to be much more aggressive about
alerting clinicians about how improper this practice is."
Dr. Sidney Wolfe, a health care activist and director of Public Citizen's Health
Research Group, questioned whether federal hearings would be warranted on an
issue of medical malfeasance that, if anything, should be more closely regulated
by authorities in Nevada.
"For better or worse, states regulate doctors," Wolfe said. "There are enough
issues here in Washington that clearly are in the domain of federal legislation
that Congress should be holding hearings on.
"It is hard to justify to hold a hearing they have no jurisdiction over."
In letters to Pallone and Stupak, Berkley contended the Las Vegas clinic scandal
"is far from an isolated case."
In 2002, 99 patients at a cancer clinic in Fremont, Neb., became infected with
hepatitis C, the largest such outbreak to date.
The Nebraska incident received a fresh wave of media attention in February,
prompting Rep. Jeff Fortenberry, R-Neb., on Feb. 25 to request House hearings on
medical errors that lead to disease spread.
In the past year, 4,500 patients in New York City were advised to be tested for
hepatitis C as a result of the practices of an anesthesiologist who participated
in their endoscopy procedures.
Also in New York, testing recommendations were issued to 10,400 patients who got
treatment at a pain management clinic in Plainview. The health department
discovered problems in January 2005 but delayed in broadcasting the warnings.
In Grand Rapids, Mich., the Kent County Health Department notified 13,500
patients of a local dermatologist that syringes had been reused and other
unsanitary practices had been discovered.
Days before the Las Vegas clinic was exposed, Rep. Anthony Weiner, D-N.Y.,
coincidentally petitioned for House hearings to examine accidental hepatitis
infections associated with misuse of syringes and multi-use vials.
Berkley said her request for hearings has been hampered by House scheduling and
she expects a decision now that Congress has returned from a two-week recess.
Richard Urey, Berkley's chief of staff, said he heard talk that the Las Vegas
health alert "is so egregious that it could only be in Nevada."
"We don't believe that is true but we have to find out," Urey said. "If we know
of Nevada and Minnesota and Seattle, and if we know it is in New York, how many
don't we know about? To say this is only in Nevada and that is why we are not
having hearings, that is bullshit."
Contact Stephens Washington Bureau Chief Steve Tetreault at
stetreault@... or (202) 783-1760.
http://www.lvrj.com/news/17255594.html

Inspiring Skippack man keeps running, despite adversity

2008-08-29 17:57:52

Inspiring Skippack man keeps running, despite adversity
By: Lisa Scull, Correspondent
A tragic and near-fatal accident took 55-year-old Denny Chipollini's leg, and a
resulting blood transfusion left him with Hepatitis C. Through these tragedies,
Chipollini, of Skippack, has allowed his spirit to soar.
"I call it a gift, not a tragedy. I've been incredibly fortunate to change my
life for the better. I've been able to do more with one leg than I have ever
been able [to do with two]," Chipollini said.
Chipollini will participate in the Valley Forge Revolutionary 5-mile Run on
April 20 at the Valley Forge National Historical Park in King of Prussia and has
inspired others to do the same.
Chipollini works in the physical therapy department at Mercy Suburban Hospital
in Norristown and as a personal trainer at Kinetix Sports Club in East Norriton.
"A team of 40 people from Kinetix will run together to support the park,"
Chipollini said. "It's a beautiful park. It'll be a great run to start the
running season off."
Since the accident, Chipollini has run marathons in San Diego, Pittsburgh,
Philadelphia and New York. He has also participated in two triathlons. He
carried the torch in the 2002 Winter Olympic Games and has been on the Montel
Williams show.
"There's motivation everywhere. You can find hope in the strangest places and
where you never thought possible," Chipollini said.
Chipollini has become a source of inspiration for others through a charitable
organization he started called Generation Hope (www.genhopeusa.org ). As a
motivational speaker, he strives to eliminate bullying in schools with an
eye-opening and honest presentation highlighting his own challenges that help
children identify and sympathize with classmates.
"If you don't treat each other with kindness and respect now, there's not going
to be a world left for anybody," Chipollini said. "I use my amputation as a
visual perception. It blows the kids away," Chipollini said.
As a personal trainer, Chipollini challenges people to get in the best shape
possible using himself as a visual example. Michael Ticcino, of Audubon, is one
person who has been inspired by Chipollini.
"I went to Denny with a pot belly. I was just not in shape. I had to do
something about it. By the time I finished the first workout with him, I was
totally committed. He got me in really good shape. He's basically my hero,"
Ticcino said.
"Mike came to the gym three years ago and, after losing 30 pounds, has become
one of the fittest men in the gym," Chipollini said.
Chipollini and Ticcino ran a 5-mile race together last year. As part of his
maintenance routine, Ticcino runs in Valley Forge National Historical Park
daily.
"I was running in the park and started to look around and absorb the history of
the place. I felt connected. I started noticing these beautiful images and
wanted to take its portrait," Ticcino said.
Ticcino owns Ticcino Creative, a graphic design business and has a newfound
passion for photography, which he shared on a photo-sharing Web site.
"I was really just doing it for myself. It's given me a real connection to
people," Ticcino said. "Little did I know that one of the administrators at the
park was following my Web progress and was kind of a fan. They contacted me and
asked if I would want to meet. An exhibit came up and they wanted to wrap my
images around the run."
The welcome center at the park houses the first of its kind exhibit, which will
be on display until the end of April.
"In telling Denny about it, I got him to do the run with me," Ticcino said.
The two have become good friends over the years and remain competitive with one
another.
"I'm running the best that I've ever run. We're great friends, but I want to
beat Mike. It's all in fun. We egg each other on," Chipollini said.
"I'm going to run my race. The last quarter mile is absolute killer. It's all
uphill. I keep trying to scare Denny off with that," Ticcino said.
Last year, the Valley Forge Revolutionary 5-mile Run had 1,300 registered
participants. Due to the anticipated turnout, there will be no race day
registration this year. The cost to register for the race is $20 for the 5-mile
run or $15 for the 3-mile walk. Youths may participate in a 1-mile walk for
free. Proceeds from the race will benefit Valley Forge National Historical Park
preservation and maintenance. To register, visit www.revolutionaryrun.org .

Will InterMune's Hepatitis C Drug Compete?

2008-08-29 11:28:42

Will InterMune's Hepatitis C Drug Compete?
By Brian Lawler April 3, 2008
http://www.fool.com
The wait was a little longer than anticipated, but investors finally got a
healthy first look at data from InterMune's (Nasdaq: ITMN) hepatitis C
treatment, ITMN-191, on Tuesday.
ITMN-191 is InterMune and partner Roche's antiviral protease inhibitor to treat
hepatitis C virus (HCV) infections. It was discovered by Array BioPharma
(Nasdaq: ARRY) and subsequently out-licensed to InterMune, which then
out-licensed it again to Roche.
Almost six years ago the FDA approved an important new compound to help treat
HCV, which is very dangerous and can lead to liver cancer. Without a doubt there
will be more in the coming years. With the success of other, similar antiviral
compounds in clinical testing, many people have been eagerly awaiting ITMN-191's
first study results.
ITMN-191 against the competition
Thankfully InterMune released enough clinical trial data on Tuesday and
Wednesday for us to be able to make initial comparisons of ITMN-191 against its
brightest competition.
So how strong is the ITMN-191 data? Here's how its 14-day phase 1 study results
compare to some other hepatitis C antiviral agents after their phase 1 14-day
monotherapy studies in genotype 1 HCV-infected patients.
Company Drug HCV mean viral
load reduction
(VLR)
InterMune and Roche ITMN-191 3.8 log* median VLR
Vertex Telaprevir 4.4 log** median VLR
Pharmasset and Roche R7128 2.7 log*** mean VLR
Roche R1626 4.1 log* median VLR
Schering-Plough Boceprevir 2.1 log^*** mean VLR
*In previously untreated patients only.
**Both previously untreated and treatment-experienced patients. ***In
treatment-experienced patients only.
^Not necessarily at end of study.
This is not a full list of top HCV drug treatments in development. Other
compounds, such as privately held ViroChem's polymerase inhibitor, have produced
similarly strong study data.
Another important factor is that all these phase 1 studies used at least
slightly different patient groups in various locations. Differences such as age,
sex, or ethnicity affect how well a drug performs. All these drugs were tested
in very few patients in these studies; some cohorts had fewer than 10 patients.
It is still too early to guess which drug candidate looks most effective. Based
on these results, all I'd be confident to say is that they all exhibit some
activity in fighting hepatitis C. Even a 2.0 log reduction in a patient's HCV
loads represents a 99% reduction in the amount of the virus in the bloodstream.
The reason I compare ITMN-191 to the other leading anti-hepatitis C treatment
candidates is to show that the drug's phase 1 results are at least comparable to
other similar compounds that are much closer to approval. (If telaprevir doesn't
get approved I will be beyond shocked.) InterMune has now officially validated
ITMN-191 as a viable anti-hepatitis C drug candidate at this stage of the game.
InterMune will start testing ITMN-191 in another phase 1b study this quarter,
this time in combination with Roche's Pegasys and ribavirin. The real test for
ITMN-191 will be in how the drug performs in long-term testing, and whether it
can produce HCV cure rates as high as some of its advanced rivals.
Investors shouldn't forget that other HCV antivirals from Wyeth (NYSE: WYE),
Achillion, and Gilead Sciences (Nasdaq: GILD) have been derailed due to negative
safety signals. ITMN-191's long-term safety in humans is still unknown.
Quality, not quantity
ITMN-191 is not InterMune's only exciting pipeline candidate, and investors will
hear more about its potential idiopathic pulmonary fibrosis treatment,
pirfenidone, by January next year when InterMune releases phase 3 results for
the drug.
InterMune doesn't have the biggest drug pipeline; only two compounds are in
clinical stage testing. Its two drug candidates don't treat the biggest
potential markets in the world. But I can say with confidence that InterMune
does have two very viable shots on goal with ITMN-191 and pirfenidone, and both
have produced very exciting data so far.
http://www.fool.com/investing/high-growth/2008/04/03/will-intermunes-hepatitis-c\
-drug-compete.aspx

1 tests positive for hepatitis; likely unrelated to nurse

2008-08-29 03:37:36

1 tests positive for hepatitis; likely unrelated to nurse
April 2, 2008 10:55 AM ET
NEWPORT NEWS, Va. (AP) - A hospital in Newport News says a patient screened for
hepatitis C tested positive, but the case is likely to be unrelated to a nurse
suspected of infecting patients at a hospital in Texas.
Riverside Regional Medical Center started screening patients last week after
discovering that a man who'd worked there was suspected of infecting patients in
Texas.
Nurse anesthetist Jon Dale Jones worked at Riverside from July through December.
Hospital spokesman Peter Glagola says test results for 122 patients screened for
hepatitis C are negative. Officials are awaiting results of about 40 other
patients that have been screened. Ninety others are scheduled for screenings.
Glagola says officials do not believe the positive result is linked, but
additional testing is being done.
http://www.wric.com/global/story.asp?s=8106248

Wellness Mental and Emotional Attitude

2008-08-29 01:02:43

Wellness Mental and Emotional Attitude
Introduction
Positive attitude
Developing and maintaining a positive mental attitude is perhaps the single most
important thing a person with hepatitis C can do for themselves. The messages we
tell ourselves dictate not only our moods and behaviour but can also have a
powerful impact on our physical condition.
This is not the same as feeling happy - it's creating a whole new outlook
despite how you may feel. Evidence suggests that many people with long-term
chronic illness who are able to maintain a positive attitude experience a slower
progression of their condition and often show better responses to treatment.
Some people find adopting a positive attitude harder than others and adding
hepatitis C into the picture is a further hindrance. Below are some pointers
that may be of use:
Remembering you are NOT your disease
Initially a diagnosis of hepatitis C eclipses everything in your life. You may
spend hours on the internet researching the virus, talking to other sufferers
and explore all the treatment options with doctors and alternative medicine
practitioners. In this environment it becomes easy to lose sight of the person
you were before your diagnosis and see yourself defined in terms of your
disease. This is not only untrue but potentially very destructive. The qualities
that make you the person you are, known and loved by your family, friends and
colleagues all remain. Should you choose to define yourself in terms of your
hepatitis C status over time so will those around you. You do not cease to be a
good father, wife, tiddly-winks player or pub quiz master on finding out you
have hepatitis C.
Those living most successfully with the virus are those who have reached an
accommodation with the virus in terms of treatment, diet and lifestyle but do
not let it restrict them from the life they would otherwise choose to live.
Living in the present
Today matters, tomorrow is unknown and yesterday is history. For many hepatitis
C sufferers it is difficult to live in the present while haunted by questions
from the past like "how did I catch this?" or concerns about the future, "what
kind of life will I have with this virus?". While it is only natural to want to
know how you became infected, ultimately it does not change your situation.
There may be a temptation to give yourself a hard time about your behaviour if
it may have led to infection but that will only result in dragging yourself down
further and further.
Those who are able to live in the present, accept their circumstances and
embrace what each day has to offer will find it much easier to maintain that
important positive attitude.
Being grateful
What are the ten things you are grateful for today? How quickly you can name the
ten is a pretty key indicator of your state of mind. In the midst of dealing
with hepatitis C it can be easy to lose sight of those things which would
otherwise be a great source of joy or support. Seeking out and celebrating those
things for which you are grateful is a powerful way of reminding yourself about
the positive things in your life. While most people will think of the love and
support of family and friends, some psychologists argue its just as important to
remember the small stuff. They advocate writing a daily list of the ten things
you are grateful for (with no repetition).
At first it might be difficult but it does get easier to recognise the small
things worth noting that make life more pleasant - the rain stopped when you had
to go out, next doors teenager has given up his heavy metal ambitions or you
found a parking meter which still had plenty of time left on it. Setting
yourself the exercise of finding things to be grateful for is guaranteed to lift
your spirits.
Setting yourself realistic goals
It is part of the of the human condition to want to grow and develop. We do this
all the time by setting ourselves goals from learning to cook a new dish to
bringing down the golf handicap. Setting and achieving goals is a powerful boost
for anyone. For those with hepatitis C, goals may revolve around treatment, how
fast you get back to work or how quickly you feel like your old self. While
achieving goals is a great tonic, setting unrealistic goals and therefore
setting yourself up to fail is destructive. No-one likes to fail, repeated
failure means you will only give yourself a hard time at a period in your life
when you need to learn to be kind to yourself.
Laughter as medicine
The ultimate physical manifestation of a positive attitude is laughter and for a
treatment that is absolutely free the benefits are astonishing. Laughter boosts
the bodys level of its own natural painkillers endorphins, it suppresses the
stress hormone epinephrine. A good giggle provides a fantastic workout for the
bodys immune system it increases to the number of virus-attacking T cells,
boosts the blood chemical transmissions in the nervous system and stimulates the
production of the antibodies that fight all sorts of infections. And if all that
isn't enough, a good belly laugh is great cardiovascular workout, raising and
lowering the heart rate and blood pressure, enhancing alertness and memory and
lifting depression.
The best part of all is that this treatment can be practised anywhere, by people
in any state of health and immediately makes them the kind of person other
people enjoy being around.
The bad stuff
With all that a positive attitude and a good laugh have going for them why is it
often so difficult for people to embrace them? One school of thought is that a
negative attitude serves some purpose for certain individuals. It means that
others will try to cheer you up or solve your problems. Nothing is ever your
fault and you absolve yourself of any responsibility if a course of action
doesnt work out the way you planned. It also means that others have no
expectations of you. A negative attitude towards your health may mean that you
accept that your health will not improve and there is no need to plan for a
future where your health has improved.
That kind of negative thinking can become a self-fulfilling prophecy. When the
benefits of a positive attitude are so well documented, even if it is difficult
to achieve, it must surely be worth the effort.
Taking responsibility
This is your life and your health. Hepatitis C is not a hopeless condition -
there is a lot you can do to help yourself. The most important thing is to
recognise that you have choices, these are in your hands and choices lead to
action. Taking responsibility for your health is a very positive and empowering
step.
Before you make any decisions or take any action, try to gather as much
information or advice as possible. For example consider what are the advantages
or disadvantages of any actions, are they in your best interests. Consider who
can help you or support you to consider all your options and where possible
involve them in formulating an action plan.
Feeling you are in control and that any decisions and actions are yours and not
ones forced upon you will result in you feeling less stressed, angry, helpless
and negative.
Understanding emotions
Discovering that you have a long-term condition is likely to challenge how you
feel about a lot of things in life and, as a result, provoke all types of
emotions. This is normal.
Sometimes we feel our emotional response is not the right one especially when
dealing with such a challenging issue as hepatitis C. You may feel you should be
putting emotions aside and try to deal with the situation from a logical point
of view. It's important to realise that both your logical and emotional
responses are equally important and each has a place. It makes sense to make
decisions about treatment from a logical perspective, but accepting that you
have a serious illness has to be done on an emotional level too.
In order to come to terms with emotions and deal with them in a constructive way
it is very important to recognise them. This is not always as easy as it sounds,
particularly if you are subjected to a barrage of several at the same time.
Equally one emotion may get lost in another for example anger very often
disguises fear. More than this the disease itself causes mood swings.
Some of the most frequently experienced emotions include the following:
Numbness
Feelings of numbness are a common response to a hepatitis C diagnosis. This may
be beneficial response, allowing you time to adjust and consider your responses.
Feelings of numbness may return at different times, and very often in response
to news that is difficult to deal with.
Sadness
This is often a recurrent emotion and should not be confused with simply feeling
unhappy. Deep sadness or grief are frequently accompanied with feelings of loss,
e.g. loss of good health; loss of a planned or particular future; loss of
ability to participate in activities that were important to you. In addition you
may experience deep sadness about the past, maybe sadness about past actions,
lost opportunities or relationships.
Anger
Feeling angry is a natural response. You may be angry at a specific person,
about a specific time in your life or about a past action. You may have feelings
of anger towards your doctor or nurse, that they may not be able to cure you of
your condition or are sending you for frequent and/or unpleasant tests. You may
feel angry towards others who do not appear to be taking your illness seriously,
or who may be impatient towards you. Angry that you feel ill or that your life
feels restricted.
Blame
You may blame someone else for your infection, possibly someone you feel
knowingly exposed you to the virus or should have protected you. You may blame
yourself, feeling that you could have prevented the infection or that, in some
way, you deserved it.
Guilt
You may feel guilty at not being able to fulfil your usual role and the
additional demands this may place on others. Guilty that you need help from
others and the time they are spending on caring for you.
Self-pity
This term is often used in a derogatory fashion to describe wallowing behaviour.
It is wise to acknowledge and understand that naturally there will be times when
you feel sorry for yourself, but it's important not to get locked into a
negative attitude that hinders or stops any positive action.
Anxiety
This is often associated with feelings of loss of control or uncertainty about
the physical and psychological changes you may be experiencing or about life in
general, the future and how relationships may be affected.
Fear
You may have fear about the future, about how your condition will progress,
symptoms you may experience, whether treatment succeeds, whether you will be
able to cope, whether your family and friends will stand by you and ultimately
fear of death.
Dealing with your emotions
Being able to deal with emotions is about acknowledging them and trying to gain
some understanding about why you have them or where they come from. It is
important to try not to get overwhelmed because this can easily lead to a
feeling of being a victim, out of control or helpless.
By acknowledging your emotions, you are accepting that they are part of dealing
with difficult situations, they do not necessarily make you a good or bad person
and you should try not to judge yourself because of them.
Once you have acknowledged that you feel angry, sad, guilty, etc you may want to
explore why you feel this way; sometimes feelings are closely linked with people
or events that have occurred in the past, or are currently occurring.
It may help to consider if you have felt this way in the past and whether the
feelings passed or changed over time and whether you want to do something to
address the feeling.
It isn't always necessary to deal with feelings. Sometimes it is much better to
allow yourself to feel angry or sad etc, as this can be part of the process of
coming to terms with things. Remember there is no right or wrong way to feel,
and no specific time for how long you should feel that way.
Sometimes new or strange emotions can be worrying and overwhelming and can lead
to unfamiliar behaviour. This may be evident to you as well as to others. If you
feel concerned or distressed about your feelings or how they are making you
behave, you may find it useful to find someone to talk to.
Perhaps it is other peoples responses to your feelings or behaviour that is
distressing? Maybe they seem impatient, distant or judgemental. Don't assume
that others will know how you are feeling. Wherever possible it is best to
communicate to others exactly how you feel, and, in return, consider how they
feel. Try to explain, if you can, why you feel this way and understand that it
will pass.
If an emotion is persistent, recurring or distressing you might want to consider
formulating ways to deal with it. For example, on days when you feel very low
but know from experience that you will probably feel better the next day then
you could try making a pact with yourself, such as I will allow myself to be sad
today/this morning on the understanding that tomorrow will be a better day. You
may be pleasantly surprised how effective this technique can be.
Some emotions, especially those that relate to a deep-rooted issue or past
experience may be very difficult to deal with or circumvent. In these instances
it may be best to allow yourself to feel this way, try to reduce the impact it
has on you by devising an action plan. This could involve organising support and
perhaps professional help. See Support.
Dealing with bad days
On a spectrum including really awful days and really good days you are likely to
have a few at either end with the rest falling somewhere in the middle. But the
relentless nature of hepatitis C can, unfortunately, challenge you with some
pretty awful days, both physically and mentally.
It is worth considering the number of ways you could deal with bad days. A word
of caution here; try to be vigilant and consider whether they are just the odd
bad day, or whether it is possible that there may be developments in your
condition that require some professional advice. Keeping a symptom and/or side
effect diary can help you to keep a check on how often you experience bad days
and whether the feelings or symptoms associated with them are becoming worse or
more frequent.
If you find the bad days increasing in frequency or intensity you should let the
person responsible for your care know, this could be your consultant or GP.
Hepatitis C infection and the treatment for hepatitis C can take an enormous
toll on you both mentally and physically. Some symptoms will simply not respond
to any efforts you make to try to combat them and may require professional
intervention.
For example depression is a recognised symptom of hepatitis C and also the
treatment. If sad or depressing days are frequent, dont suffer in silence, speak
to your doctor, who may be able to prescribe something that will really help.
Equally treatment is available to combat or alleviate some physical symptoms
such as fatigue and pain.
Physically bad days may be easier to deal with in some ways. Feeling too tired
or too sick to do what you wanted to do, or planned to do, can be frustrating.
Try to have a contingency plan that requires little energy for those days,
perhaps a video or good book stored away for such days. Maybe you could keep a
ready prepared meal in the freezer or plenty of tinned food in the cupboard for
when you don't feel up to cooking. Having a plan of action that means you are
able to get through the day, ready to fight the next, will make you feel more in
control of things. You could perhaps use these days for planning how you will
spend you next good day, that way they do not feel wasted.
If your bad day is because you feel less able to cope or are feeling depressed
then there are still a number of things you can do. Firstly, try to accept that
some days will be better than others and take one day at a time, give yourself
some space and allow yourself to feel down or fed-up on occasions. Give some
thought as to why this may be, whether there was a trigger or a pattern and if
there is anything you could have done to prevent it. It is most likely that you
will not have all the answers to these questions, but they are worth
considering.
Sometimes simple things can make a difference. For example physical exercise, if
you feel up to it, is known to boost brain chemicals that have a positive impact
on mood, taking a walk or a gentle swim may help, but be careful not to tire
yourself out.
Consider whether it is possible that a pattern of negative thinking may have
developed, which may not be your fault. For example, is this your usual response
when things become too difficult? Maybe it is something you have learnt over a
long period of time, possibly from others. If this is possible and you feel that
you want to address it, you could ask yourself what you are likely to gain from
this way of thinking? Is it beneficial to you in the long term?
Changing patterns of thought and behaviour can be extremely difficult. Most of
our habits and behaviours have developed over long periods of time and very
often are unconscious. As a consequence we may be unaware of them or if we are
aware and want to change them this often requires a great deal of unlearning,
commitment and perseverance. Firstly, be vigilant; look out for signs that
negative thoughts are creeping in. Secondly, remind yourself why you do not want
this to occur. Thirdly, devise a plan of action: This may seem a simplistic
example but its amazing how a different kind of response can actually make a
significant difference:
Let's say you wake up one morning and can't be bothered to get washed and
dressed. This is not a good sign. You remember last time this happened you didnt
get washed or dressed and only ate crisps for five days. By the end of the five
days you were so depressed and it took three weeks before you were back to
normal again. So perhaps this time you accept that you dont feel great but you
immediately turn on the bath and make yourself a hot drink. Whilst relaxing in
the bath you make a mental list of things you could do that day, that are
positive but not too taxing. This could include making contact with someone, a
visit or a phone call, taking a walk and doing one thing that is practical and
one thing that is pleasurable. Allow plenty of time to do each thing so that you
are not rushed or putting pressure on yourself.
Make a mental note of what you have achieved at the end of the day and you can
see that you changed the way you responded to a negative start to the day. Once
you get the start to the day sorted out, the rest often follows. If you are able
to achieve this on most occasions, then eventually you may learn a new response
to habitual negative thinking .
The danger of being isolated
Feeling isolated alone or depressed is a very common reaction to any illness and
one that relates not so much to being alone but rather to feeling alone despite
having others around you. Loneliness can stem from feeling that nobody
understands what you are going through, or that you are somehow different from
others or abnormal.
Sometimes it is important and necessary to be on your own, this allows you time
to think and reflect. But choosing to be on your own and feeling isolated are
two very different things. The danger of isolating yourself is that negativity
can build with no-one to counteract it. Then you may feel worse and, as a
consequence, get worse and so a vicious circle can develop.
It is important to be aware of this downward spiral and if you find it
happening, to seek contact with someone rather than cut yourself off. If you
find yourself feeling isolated and don't have anyone you feel able to contact,
please see our Support section.
Wherever possible, try to maintain your usual contacts. You may need to make
adjustments if you have less energy, less money or feel less active. But, as far
as possible keep in contact with those people who have been important to you.
Sometimes it is enough to have just one or two close friends who are there for
you.
Another important feature of being isolated is that it can cut you off from
essential information about the disease, about treatment and about places to get
help. Stay in touch with healthcare professionals and hepatitis C related
organisations and support groups so that you can stay informed.
New Relationships
If you don't have people who are able to understand how you are affected by
hepatitis C, then you may need to look for support in new relationships. For
example, if you are fortunate to have a hepatitis C support or self help group
in your area you may consider contacting them. Very often they facilitate
drop-ins or meetings where you can meet others with hepatitis C. Sharing
information and concerns can alleviate some of the loneliness and isolation.
Dealing with other people
Hepatitis C can make dealing with other people particularly challenging in a
number of ways. Commonly those with hepatitis C experience mood swings, feel
very irritated and short tempered, self-absorbed, intolerant, tired, depressed
and worn down. If you are aware of this and the fact that often your reactions
are being provoked by the disease itself, it becomes easier to react less to
people. The problem of failing to temper your reactions is that it pushes people
away, in particular those closest to you and these are exactly the people whose
support is the most valuable. Understanding the nature of hepatitis C, mood
swings, depression etc. helps to create the possibility of not taking your
emotional state so personally.
Emotional inconsistency can make people nervous of you. Ensuring that others
understand that your behaviour is often provoked by the virus will mean that
they are less likely to take things personally. This is not to say that these
mood swings are an excuse for being inconsiderate or badly behaved. Being aware
of your vulnerability to mood swings and the impact they can have on you and
others close to you is key to enabling you to take some control over them.
http://www.hepctrust.org.uk/Wellness/mental-and-emotional-attitude/

Indian doc's passport 'flagged', US police say cannot charge him

2008-08-28 20:24:17

Indian doc's passport 'flagged', US police say cannot charge him
SILICON VALLEY: Authorities have "flagged" the passport of Dipak Desai, the
Indian-American owner of a Las Vegas clinic chain that is at the centre of one
of the biggest malpractices scandal in the US, with the police saying the probe
"is not far enough" to charge the doctor.
Although flagging of Desai's passport will not prevent him from leaving the
country, it would notify law enforcement officials and allow them to interview
Desai before he leaves the US, according to sources close to the investigation.
The scandal came to light last month after it was alleged that the staff were
reusing medical supplies including syringes and vials at his Endoscopy Center,
triggering a major healthscare.
It prompted authorities to notify about 40,000 patients that they should be
tested for hepatitis B, hepatitis C and HIV.
Desai's Endoscopy Centre of Southern Nevada was closed after officials confirmed
that six people had been infected with hepatitis C because of unsafe medical
practices at the clinic.
Metro Police Deputy Chief Kathy Suey said Desai is "absolutely one of the
persons we're looking at in the investigation," reported the Las Vegas Sun
newspaper.
However, that investigation "is not far enough to charge him with something" at
this time, Suey added.
It was unclear whether it was the local or the federal agencies that had
requested the action in regard to Desai's passport, the paper said.
Desai's attorney Richard Wright refused to comment on his client's passport
being flagged, the paper reported.
He also refused to confirm authorities' belief that his client is still in Las
Vegas, saying it is a private matter.
http://timesofindia.indiatimes.com/Indians_Abroad/Indian_docs_passport_flagged_U\
S_police_say_cannot_charge_him/rssarticleshow/2919509.cms

single

2008-08-28 17:06:37

Can't seem to find any single female post.most sites are way
outdated.49yo in wa state.help,thanks

Once-Daily Insulin More Convenient but No More Effective

2008-08-28 03:07:34

Once-Daily Insulin More Convenient but No More Effective
By Crystal Phend, Staff Writer, MedPage Today
Published: March 28, 2008
Reviewed by Zalman S. Agus, MD; Emeritus Professor
University of Pennsylvania School of Medicine.
GIESSEN, Germany, March 28 -- Once-daily injections of insulin glargine (Lantus)
may control type 2 diabetes as well as multiple injections of insulin lispro
(Humalog) and reduce side effects at the same time, researchers here found.
Basal insulin therapy had a similar effect on glycosylated hemoglobin A1c
levels as prandial insulin (1.7% versus 1.9% reduction) but yielded 78% fewer
hypoglycemic events, less weight gain, and greater patient satisfaction,
reported Thomas Linn, M.D., Ph.D., of Justus Liebig University Giessen, and
colleagues in the March 29 issue of The Lancet.
"Insulin glargine provides a simple and effective option that is more
satisfactory to patients than is lispro for early initiation of insulin
therapy," they wrote.
The findings also help address the ongoing debate over whether to target
therapy to fasting glucose or postprandial glucose, said Yogish C. Kudva,
M.B.B.S., and Victor M. Montori, M.D., of the Mayo Clinic in Rochester, Minn.,
in an accompanying editorial.
But the issue will not be settled until studies link improvements to
outcomes that matter to patients, such as diabetes complications, Drs. Kudva and
Montori said.
The APOLLO (A Parallel design comparing an Oral antidiabetic drug
combination therapy with either Lantus once daily or Lispro at mealtime in type
2 diabetes patients failing Oral treatment) was a non-inferiority study funded
and done by the makers of the basal insulin under evaluation.
It included 205 type 2 diabetes patients randomly assigned to open-label
insulin glargine once daily at the same time every day and 210 patients
randomized to insulin lispro three times daily before meals.
All the patients had hemoglobin A1c concentrations between 7.5% and 10.5%
and fasting blood glucose concentrations of 6.7 mmol/L or more despite being on
stable doses of oral antidiabetic agents.
Most patients in both groups remained on metformin (74% to 76%) and
glimepiride (Amaryl, 93% to 94%) throughout the trial.
After 44 weeks of treatment, mean hemoglobin A1c decreased from 8.7% to
7.0% in the insulin glargine group and from 8.7% to 6.8% in the insulin lispro
group (P<0.0001 for both).
The similar adjusted mean change between groups met criteria for
noninferiority in both the per protocol and intent-to-treat analyses (0.137%
difference, 95% CI -0.022 to 0.297, P=0.0908).
Despite the debate about whether fasting or postprandial blood glucose
concentrations have a greater effect on hemoglobin A1c, the researchers said,
"our data suggest that the reduction of hemoglobin A1c is more dependent on
targeted insulin therapy per se rather than on a specific glucose profile."
As expected, though, insulin glargine reduced nocturnal blood glucose and
morning fasting glucose better whereas postprandial glucose levels were better
with insulin lispro.
More patients in the insulin lispro group than in the insulin glargine
group reached hemoglobin A1c targets, including:
a.. 7% or less (69% versus 57%)
b.. 6.5% to 7% (30% versus 27%)
c.. Less than 6.5% (38% versus 30%)
But more patients reached target fasting blood glucose concentrations of
5.5 mmol/L or less with insulin glargine than with insulin lispro by the end of
the study (35% versus 5% in the intent-to-treat analysis, P<0.0001).
Insulin lispro better controlled postprandial blood glucose throughout the
day (P<0.0001).
Hypoglycemia events were substantially less common with insulin glargine
than with insulin lispro (4.27 versus 19.46 per patient, P<0.0001), although
severe events were not significantly different between groups.
Weight gain from baseline tended to be lower with insulin glargine (3.01
versus 3.54 kg, P=0.23).
While patients in both groups reported a fairly high level of satisfaction
with treatment, insulin glargine-treated patients had significantly greater
increases in satisfaction than lispro-treated patients (P<0.0001).
Notably, satisfaction scores related to convenience of treatment worsened
in the lispro group compared with baseline but improved in the glargine group.
These advantages for insulin glargine may help poorly controlled patients
accept making a timely shift from oral agents alone to the addition of insulin,
the researchers concluded.
The study was funded by sanofi-aventis, which makes insulin
glargine.
Dr. Linn reported receiving an unrestricted research grant from
sanofi-aventis. His co-authors reported conflicts of interest for
sanofi-aventis, Bayer, Develogen, GlaxoSmithKline, Lilly, MSD, Novo Nordisk,
Pfizer, Roche, and Novartis. One of the authors reported holding a copyright for
the diabetes treatment satisfaction questionnaire and being director of Health
Psychology Research that licenses questionnaires to pharmaceutical
companies.
Dr. Kudva reported receiving funding for a research trial from
sanofi-aventis. Dr. Montori declared no conflicts of interest.
Primary source: The Lancet
Source reference:
Bretzel RG, et al "Once-daily basal insulin glargine versus thrice-daily
prandial insulin lispro in people with type 2 diabetes on oral hypoglycemia
agents (APOLLO): An open randomized controlled trial" Lancet 2008; 371: 1073-84.
Additional source: The Lancet
Source reference:
Kudva YC, Montori VM "Patient-centered treatments for type 2 diabetes"
Lancet 2008; 371: 1047-48.
Related Article(s):
a.. ADA: More Convenient Insulin Regimens May Give Same Control of Type
2 Diabetes
http://www.medpagetoday.com/Nephrology/Diabetes/tb/8935

Man saved by donated liver spreading the word

2008-08-28 00:29:18

Man saved by donated liver spreading the word
Couple sharing story at DMV to encourage potential donors
By Anna Chang-Yen
Correspondent
Monday, March 31, 2008
George and Lucille Miller of Ventura know better than most people how much organ
donation can mean. Ten years ago, after George Miller's liver failed and doctors
gave him 48 hours to live, a donated liver saved his life.
The Millers will share information about organ donation Tuesday at the
Department of Motor Vehicles office in Santa Paula, where people can add their
name to the California Organ and Tissue Donor Registry.
April is national Donate Life Month.
Nonalcoholic steatohepatitis claimed George Miller's liver. It happened
suddenly, and the Millers had never considered organ donation. They thought a
liver transplant would be an experimental procedure.
They soon learned that UCLA Medical Center, where he was being treated, performs
thousands of transplants a year.
The decision by the family of a 33-year-old woman who died after suffering a
brain aneurysm would save Miller's life. The woman's mother said she didn't
remember discussing organ donation with her daughter, but a check of her
driver's license turned up a pink dot - a sign that a California resident has
signed up for the state registry, Lucille Miller said.
"My husband's alive today because of her generosity," she said. "It's a gift of
life that you just can't say thank you enough for. That's why it's so important
to us."
This year, the Millers will celebrate three milestones with their
granddaughters: one college graduation and two high school graduations. They are
milestones that George Miller might not have been around to help celebrate had
it not been for organ donation.
So the Millers reach out to help others understand how much their decision to
donate organs can affect others. As ambassadors for One Legacy, a donor network,
they make presentations at schools, churches and civic group meetings and attend
health fairs and other events to spread the word.
"People have to understand it. People have to be very charitable about it,"
George Miller said. "Our friends are dying, too many other people are dying, and
the only answer is organs."
He recalled the story of a woman who asked family members to donate a kidney -
the human body has two, and donors can live with one after a transplant. None
was willing to help, and she died six months later. "It made me really angry
when I found out she passed away," he said. "God gave us two kidneys - one to
use and one to give away."
One Legacy estimates that across the country, more than 86,000 people are
waiting for organ transplants, including more than 2,000 people younger than 18.
Although family members have the ultimate say when it comes to donating a
deceased loved one's organs, signing up for the registry can signal a person's
intentions even if they never discussed the matter with family members, Lucille
Miller said.
The Millers will be at the DMV office at 250 Harvard Blvd., Santa Paula, from 9
a.m. to 1 p.m. Tuesday.
On the Net:
United Network for Organ Sharing: http://www.unos.org
One Legacy: http://www.onelegacy.org
Donate Life California Organ and Tissue Donor Registry
http://www.donatelifecalifornia.org
http://www.venturacountystar.com:80/news/2008/mar/31/man-saved-by-donated-liver-\
spreading-the-word/

Cirrhosis videos and more...............

2008-08-27 20:01:01

If you can't handle looking at real medical pictures of our livers please do not
click on most of these links.
Cirrhosis
http://www.youtube.com/watch?v=ex5wUWrZubo&feature=related
Alcoholism, Cirrhosis, and Medical-Social Issues
http://www.youtube.com/watch?v=C4WNroXVjK4&feature=related
Histology of the Liver
http://www.youtube.com/watch?v=KtFJvlEDE2I&feature=related
Histopathology Liver--Alcoholic liver disease
http://www.youtube.com/watch?v=VhQQnAkClN4&feature=related
How the Body Works : The Architecture of the Liver
http://www.youtube.com/watch?v=Gn-ibhGE7PI&feature=related
Hepatic Circulation
http://www.youtube.com/watch?v=pQMmMUXXttI&feature=related
The Liver
http://www.youtube.com/watch?v=1RqqF7tZBYg&feature=related

CDC announces year's first fatal hepatitis A case

2008-08-27 11:32:04

CDC announces year's first fatal hepatitis A case
SANITATION: CDC Deputy Director Lin Ting urged people, especially those who
habitually eat out, to take extra precautionary measures when it comes to food
STAFF WRITER, WITH CNA
Tuesday, Apr 01, 2008, Page 2
The Centers for Disease Control (CDC) yesterday announced this year's first
fatal case of hepatitis A. The victim was a 30-year-old man who died four days
after he was hospitalized.
So far this year, 82 new cases of hepatitis A have been reported, 47 affecting
people under the age of 30.
"We strongly advise young people to pay particular attention to food sanitation
when dining out," said CDC Deputy Director Lin Ting (ªL³»), urging people to
avoid drinking untreated water and eating food from unknown sources.
Lin said the man was sent to a hospital in southern Taiwan on March 11. He was
reportedly unconscious by the time he was brought in. The local CDC was notified
the next day of his case. The man died of liver and kidney failure on March 14.
Autopsy reports later confirmed the underlying cause of death was hepatitis A,
Lin said, urging people, especially those who habitually eat out, to take extra
precautionary measures to inspect the cleanliness of food in restaurants.
"In earlier years, hepatitis A was very prevalent in Taiwan. Most people above
the age of 50 are carriers. However, the drastic improvement in water and food
sanitation efforts by the government has greatly reduced the transmission of the
disease," Lin said.
But the high rate of infection this year so far, he said, has become an alarming
cause of worry for the government.
Hepatitis A is a liver disease caused by the hepatitis A virus. The symptoms
include jaundice, nausea, vomiting, fatigue, loss of appetite, diarrhea,
abdominal pain and fever.
It is usually spread from person to person by contact with the stool of a person
infected with hepatitis A. According to CDC statistics, only 42 new cases of
hepatitis A infection were reported at this time last year. The numbers for the
previous four years were 57, 62, 49 and 45.
The sharp increase this year, especially among people under the age of 30, shows
that young people are more prone to the disease.
The young people's lack of antibodies and their habit of eating out, coupled
with increasing tourism to and from Southeast Asia and China have all
contributed to the recent hike, he said.
A hepatitis A vaccine is available in Taiwan. Those who are interested in
getting boosters should contact their local health authority. The cost for
adults is approximately NT$1,500 to NT$2,000 for each dosage and NT$1,000 for
children. People must receive dosages to gain the maximum protection against the
infectious disease.
http://www.taipeitimes.com/News/taiwan/archives/2008/04/01/2003407885

Police: Woman bit hospital staff

2008-08-27 06:45:18

Police: Woman bit hospital staff
A woman infected with Hepatitis C was receiving treatment at LSU Health
Services in Monroe when she bit two staff members and was arrested, according to
a police report.
Shaquanta Walters, 29, 9A Row Dr., was charged with two counts of
aggravated battery.
According to the report, Walters was trying to remove stitches from her wrist
with her teeth and was constrained by staff members. During this time, she
reportedly bit a security guard's biceps and a nurse's index finger. The guard's
arm required treatment because the bite broke skin causing him to bleed. The
arrest report indicates that hospital workers believe Walters was trying to bite
them knowing that she was infected with Hepatitis C.
Walters was booked into Ouachita Correctional Center.
http://www.thenewsstar.com/apps/pbcs.dll/article?AID=/20080331/NEWS01/803310321

Live in Hawaii? Interested in a clinical trial?

2008-08-27 00:58:44

For Immediate Release -
To people with Hepatitis C and their health care providers
Hepatitis C is a silent epidemic with nearly one in 50 Americans infected.
If left unchecked, complications such as cirrhosis, liver failure and liver
cancer may occur. Many people who are infected with hepatitis C will not feel
ill until irreversible damage is done.
We are now starting a clinical trial study to learn how long Hepatitis C
genotypes 2 and 3 need to be treated.
If a person with hepatitis types 2 or 3 still has virus on standard interferon
and ribavirin therapy after 4 weeks, people will receive study medications,
tests, and medical care at no cost for at least 24 weeks.
If you would like to know more or if you would like to refer a patient for
consultation, please call Infections Limited Hawaii to speak with Alan Tice, MD
or Yang Shin, PA-C at their office - 373-3488.

Vertex Pharmaceuticals Announces Acceptance of Late-Breaker Abstract on Telaprevir, Investigational HCV Protease Inhibitor, for Presentation at EASL Annual Meeting

2008-08-26 21:33:30

Vertex Pharmaceuticals Announces Acceptance of Late-Breaker Abstract on
Telaprevir, Investigational HCV Protease Inhibitor, for Presentation at EASL
Annual Meeting
Monday March 31, 8:31 am ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq:
VRTX - News) today announced that data related to its investigational hepatitis
C protease inhibitor telaprevir will be featured in a late-breaker poster
presentation during the 43rd Annual Meeting of the European Association for the
Study of the Liver (EASL) in Milan, April 23-27, 2008.
The title of the abstract is "A Study of Telaprevir (TVR) with Peginterferon
alfa-2A (P) and Ribavirin (R) in Subjects with Well-documented Prior P/R Null
Response, Non-Response or Relapse: Preliminary Results" and will be presented at
EASL starting on Thursday, April 24. Accepted late-breaker abstracts for the
EASL meeting are now available on the EASL website. Information contained in the
late-breaker poster abstract has also been filed by Vertex with the U.S.
Securities and Exchange Commission on a Form 8-K.
In addition to the late-breaker abstract, three additional abstracts on
telaprevir have been accepted for presentation during EASL:
Oral Presentations:
PROVE 1: Results From a Phase 2 Study of Telaprevir with Peginterferon alfa-2a
and Ribavirin in Treatment-Naïve Subjects with Hepatitis C; Thursday; April 24
at 3:45 p.m. CET (9:45 a.m EDT).
Treatment of Chronic Hepatitis C with Telaprevir (TVR) in Combination with
Peginterferon-alfa-2a with or without Ribavirin: Further Interim Analysis
Results of the PROVE2 Study; Friday, April 25 at 11:45 a.m. CET (6:45 a.m EDT).
Poster Presentation:
Natural Prevalence Of HCV Variants with Decreased Susceptibility to NS3.4a
Protease Inhibitors in Treatment-Naïve Subjects; starting Thursday, April 24 at
7:00 p.m. CET (1:00 p.m EDT).
About Telaprevir
Telaprevir (VX-950) is an investigational oral inhibitor of HCV protease, an
enzyme essential for viral replication, and is one of the most advanced
investigational antiviral agents in development that specifically targets HCV.
About Hepatitis C
Hepatitis C is a liver disease caused by the hepatitis C virus, which is found
in the blood of people with the disease. HCV, a serious public health concern
affecting 3.4 million individuals in the United States, is spread through direct
contact with the blood of infected people. Though many people with hepatitis C
may not experience symptoms, others may have symptoms such as jaundice,
abdominal pain, fatigue and fever. Chronic hepatitis C significantly increases a
person's risk for developing long-term infection, chronic liver disease,
cirrhosis or death. The burden of liver disease associated with HCV infection is
increasing, and current therapies typically provide sustained benefit in less
than half of patients with genotype 1 HCV, the most common strain of the virus.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed
to the discovery and development of breakthrough small molecule drugs for
serious diseases. The Company's strategy is to commercialize its products both
independently and in collaboration with major pharmaceutical companies. Vertex's
product pipeline is focused on viral diseases, inflammation, autoimmune
diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV
protease inhibitor, Lexiva, with GlaxoSmithKline.
Safe Harbor Statement
This press release contains a forward-looking statement that telaprevir data
will be featured in a late-breaker poster presentation at EASL starting on April
24. While we believe this statement to be correct, it is based on information we
have received from EASL and that information is subject to future developments
that could adversely affect the content, timing or form of that presentation.
(VRTX - GEN)
Contact:
Vertex Pharmaceuticals Incorporated
Michael Partridge, 617-444-6108
Senior Director, Strategic Communications
or
Lora Pike, 617-444-6755
Manager, Investor Relations

In Vivo Experimental HCV Vaccine Shows Promise; Dynavax/Merck HBV Vaccine Candidate Put on Hold Due to Safety Concerns

2008-08-26 08:13:35

In Vivo Experimental HCV Vaccine Shows Promise; Dynavax/Merck HBV Vaccine
Candidate Put on Hold Due to Safety Concerns
On March 17, two research collaborations made announcements about their work on
viral hepatitis vaccines
Inovio Biomedical Corporation announced results from a Swedish study showing
that a vaccine candidate the company developing with Sweden's Tripep AB ---
known as ChronVac-C -- stimulated an immune response against the hepatitis C
virus (HCV). There is currently no vaccine to prevent HCV infection. The
Inovio/Tripep product is designed to clear HCV in people who are already
infected.
The same day, Dynavax and Merck & Co. reported that the U.S. Food and Drug
Administration (FDA) has put a hold on clinical trials of the Heplisav hepatitis
B virus (HBV) vaccine candidate after one individual in a Phase III clinical
trial developed blood vessel inflammation. However, this condition has not
previously been seen in about 2500 participants in 10 trials, and it is not
clear that it is associated with the vaccine. Prior results indicated that
Heplisav compared favorably with an approved HBV vaccine, GlaxoSmithKline's
Engerix-B.
Below are excerpts from the press releases from both collaborations:
Hepatitis C Virus DNA Vaccine Shows Safety When Delivered by Inovio
Biomedical's Electroporation Delivery System in Phase I/II Clinical Study at
Karolinska University Hospital
SAN DIEGO, Mar 17, 2008 (BUSINESS WIRE) -- Inovio Biomedical Corporation
(AMEX:INO), a leader in enabling the development of DNA vaccines using
electroporation-based DNA delivery, announced today that its partner, Tripep AB
of Sweden, has reported preliminary results from the first patient to complete
treatment with Tripep's therapeutic hepatitis C virus (HCV) vaccine, ChronVac-C,
which was delivered using Inovio's electroporation-based DNA delivery system.
In this phase I/II clinical study, the treatment has so far been safe and
tolerable. Samples taken before, during and after treatment showed that before
vaccination the patient did not have a detectable cell-mediated immune response
against HCV but such an immune response became detectable after treatment was
completed. Inovio's electroporation delivery technology is intended to enhance
the potency of DNA-based immunotherapies, including DNA vaccines, against
cancers and infectious diseases.
ChronVac-C is a therapeutic DNA vaccine being given to individuals already
infected with hepatitis C virus with the aim to clear the infection by boosting
a cell-mediated immune response against the virus. It is known that patients who
spontaneously clear their infection have also developed this type of immune
response.
This clinical study is being conducted at the Infectious Disease Clinic
and Center for Gastroenterology at the Karolinska University Hospital in
Huddinge and Solna (Sweden), respectively. Intended enrollment is 12 patients
divided into three dose groups with increasing doses of ChronVac-C. Each patient
receives four ChronVac-C vaccinations one month apart. After the last
vaccination, patients are followed for another six months. The study's main
purpose is to assess safety. It is also testing whether the treatment boosts the
immune response to HCV and its effect on virus replication in the liver. If the
patient is completely virus-free six months after completing treatment, he/she
will be considered cured. This first reported data was from the first patient in
the lowest dose group. Five patients have been treated and no unexpected side
effects have been observed.
"We are pleased that this first infectious disease DNA vaccine to be
delivered in humans using electroporation-based DNA delivery has provided
initial evidence of being safe and inducing a cell mediated immune response
against the hepatitis C virus," stated Avtar Dhillon, MD, Inovio's president and
CEO. "We look forward to seeing additional data, particularly from the higher
dose groups, relating to this potential treatment to a pervasive and
difficult-to-treat disease."
About Hepatitis C and ChronVac-C
Hepatitis is a disease characterized by inflammation of the liver.
Hepatitis C virus (HCV) is spread primarily by direct contact with human blood,
the major causes worldwide being the use of unscreened blood transfusions and
re-use of inadequately sterilized needles and syringes. As many as 70% - 90% of
newly infected patients may progress to develop chronic infection (WHO: 2002).
Of those with chronic liver disease, 5% - 20% may develop cirrhosis. About 5% of
infected persons may die from the consequences of long term infection (due to
liver cancer or cirrhosis). Globally, an estimated 170 million people are
chronically infected with HCV, representing a reservoir sufficiently large for
HCV to persist, and 3 to 4 million persons are newly infected each year. In the
US, while new incidences of HCV have dropped dramatically, an estimated 4.1
million Americans have been infected with HCV, of whom 3.2 million are
chronically infected (Centers for Disease Control and Prevention: 2006). The
total market for therapies against hepatitis C infections is estimated to be
over 2 billion dollars and is expected to grow to more than 8 billion dollars by
2015.
HCV infections in the liver do not trigger an immune response very
effectively. Certain antiviral therapies, while expensive, are somewhat
effective in treating hepatitis C. There is no vaccine currently available to
prevent hepatitis C. ChronVac-C is a therapeutic DNA vaccine designed with the
aim of stimulating the body's immune system. Animal experiments demonstrated
that ChronVac-C vaccination activated B-cells and T-cells (the latter being
regarded as the most significant to clearing the chronic infection relating to
hepatitis C) that killed cells producing HCV protein. In humans, the ChronVac-C
DNA plasmid is being injected into muscle tissue, where vaccinations are usually
given, and taken up by muscle cells with the assistance of Inovio's
electroporation-based DNA delivery system. These muscle cells are expected to
produce predetermined antigens that may activate the body's immune system to
attack all cells producing HCV proteins.
About Tripep AB
Tripep AB is a Swedish biotechnology research company that develops and
commercializes candidate drugs based on patented and proprietary technologies.
Its main focuses are research and clinical development of ChronVac-C, a
therapeutic vaccine against hepatitis C; preclinical research focusing on the
development of therapeutic and prophylactic vaccines against influenza A and
HIV; and the RAS technology platform. More information is at www.tripep.se.
About Inovio Biomedical Corporation
Inovio Biomedical (AMEX:INO) is focused on developing multiple DNA-based
immunotherapies and DNA vaccines. Inovio is a leader in developing human
applications of electroporation which uses brief, controlled electrical pulses
to increase cellular uptake of a useful biopharmaceutical. Human data has shown
that Inovio's electroporation-based DNA delivery technology can significantly
increase gene expression and immune responses from DNA vaccines. Immunotherapy
partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer
Center, the U.S. Army, National Cancer Institute, and International Aids Vaccine
Initiative. Inovio's technology is protected by an extensive patent portfolio
covering in vivo electroporation. More information is available at
www.inovio.com.
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational
Vaccine HEPLISAV
Berkeley, CA and Whitehouse Station, NJ -- March 17, 2008 - Dynavax
Technologies Corporation (Nasdaq: DVAX) and Merck & Co., Inc. announced today
that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on
the two Investigational New Drug (IND) applications for HEPLISAV, an
investigational hepatitis B vaccine being jointly developed for use in adults by
Dynavax and Merck. A clinical hold is an order issued by FDA to the sponsor to
delay a proposed clinical trial or suspend an ongoing clinical trial.
The FDA has placed the clinical hold on the investigational vaccine
because of a serious adverse event (SAE) that occurred in one subject who
received HEPLISAV in a Phase 3 study being conducted outside the United States.
The subject was preliminarily diagnosed as having Wegener's granulomatosis, an
uncommon disease in which the blood vessels are inflamed. All subjects in this
Phase 3 study have received all doses per the study protocol and all will
continue to be monitored. Administration of vaccine has been suspended in the
only study of HEPLISAV in which injections were being administered actively, a
fully enrolled Phase 2 study in End Stage Renal Disease subjects being conducted
in Canada. A total of approximately 2,500 individuals have been vaccinated with
more than 5,000 doses of HEPLISAV in 10 clinical trials spanning approximately
seven years. There were no prior reports of Wegener's granulomatosis in these
trials.
No additional clinical trials with HEPLISAV will be initiated until the
clinical hold has been resolved. Dynavax and Merck, along with additional
collaborators, including clinical investigators and leading experts, are
evaluating the medical history of the individual who experienced the SAE to
understand better the timing and onset of the disease symptoms, including
whether it was a pre-existing condition or was related to vaccine
administration.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to
commercialize innovative TLR9 agonist-based products to treat and prevent
infectious diseases, allergies, cancer, and chronic inflammatory diseases using
versatile, proprietary approaches that alter immune system responses in highly
specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or
ISS, which are short DNA sequences that enhance the ability of the immune system
to fight disease and control chronic inflammation. Our product candidates
include: HEPLISAV, a hepatitis B vaccine in Phase 3 partnered with Merck & Co.
Inc.; TOLAMBA, a ragweed allergy immunotherapy in Phase 2; a therapy for
non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in
Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma
and COPD program is partnered with AstraZeneca. The National Institutes of
Health (NIH) partially funds our preclinical work on a vaccine for influenza.
Symphony Dynamo, Inc. (SDI) funds our colorectal cancer trials and our
preclinical hepatitis C therapeutic program, and Deerfield Management has
committed funding for our allergy programs. While Deerfield, NIH and SDI provide
program support, Dynavax has retained rights to seek strategic partners for
future development and commercialization. For more information, please visit
http://www.dynavax.com.
About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical company
dedicated to putting patients first. Established in 1891, Merck currently
discovers, develops, manufactures and markets vaccines and medicines to address
unmet medical needs. The Company devotes extensive efforts to increase access to
medicines through far-reaching programs that not only donate Merck medicines but
help deliver them to the people who need them. Merck also publishes unbiased
health information as a not-for-profit service. For more information, visit
www.merck.com.
4/01/08
Sources
Inovio Biomedical Corporation. Hepatitis C Virus DNA Vaccine Shows Safety When
Delivered by Inovio Biomedical's Electroporation Delivery System in Phase I/II
Clinical Study at Karolinska University Hospital. Press release. March 17, 2008.
Dynavax and Merck. Dynavax and Merck & Co., Inc. Report Clinical Hold of
Investigational Vaccine HEPLISAV. Press release. March 17, 2008.
http://www.hivandhepatitis.com/hep_c/news/2008/040108_c.html
Peace and Love
(`'·.¸(`'·.¸ ¸.·'´) ¸.·'´)
«´¨ *Pam* ¨`»
(¸.·'´(¸.·'´ `'·.¸)`' ·.¸)
¸.·´
( `·.¸
`·.¸ )
¸.·)´
(.·´
`*.
*.
Mahatma Gandhi put it well: "Be the change you want to see in the
world." It always begins with one person.

New Network Will Send Drug Alerts Instantly to U.S. Doctors via Email

2008-08-26 03:43:58

New Network Will Send Drug Alerts Instantly to U.S. Doctors via Email
A new network to deliver drug safety alerts online to U.S. physicians was
launched last week, replacing a widely criticized and decades-old system based
upon paper and U.S. mail. The Health Care Notification Network ("HCNN") is the
result of a three-year effort and an unprecedented collaboration between U.S.
medical society leaders, liability carriers, health plans, consumer advocacy
groups, government leaders, and industry, including major pharmaceutical
manufacturers.
The HCNN will also be available for rapid communication with physicians in the
event of emergency public health or bio-terror events.
Recent surveys of practicing physicians reveal that well over 90% of physicians
want drug safety alerts sent immediately online instead of on paper via U.S.
mail, and well over half wish to have a copy of the alerts also sent online to
office staff. The network is free to all licensed U.S. physicians, and is used
solely for patient safety alerts, not for advertising or promotion. It ensures
the most rapid and effective delivery of important alerts to physicians, thereby
improving patient safety and office efficiency while reducing liability and
paperwork.
"Relying on paper-based U.S. mail and weeks of delay to deliver time-urgent
patient safety alerts to doctors in 2008 is indefensible and unsafe," explained
Nancy Dickey, MD, former American Medical Association president and chair of the
Health Alliance, the not-for-profit board that governs the new HCNN service.
"After a few years of work with the FDA and many other partners, we are finally
moving from the Paper Age into the Internet Age in terms of patient safety
alerts. We encourage all U.S. physicians to take 2 minutes and enroll today at
http://www.hcnn.net. Physicians and their patients will realize immediate
benefit."
"The majority of U.S. liability carriers are asking their insured physicians to
enroll today in the HCNN because delivering product recalls and warnings
immediately online has the potential to directly improve patient safety and
reduce malpractice claims-and, ultimately, decrease malpractice insurance
premiums," said iHealth Alliance Board Member, David Troxel, MD, medical
director for The Doctors Company, the country's largest physician-owned
liability carrier.
The iHealth Alliance credits FDA leadership for making the HCNN and immediate
online patient safety alerts for physicians a reality, as the FDA recently
updated its guidance for the pharmaceutical and device industry, and now
actively encourages the use of online networks for patient safety alerts.
"Letters to health care providers often are screened by one or more
'gatekeepers' and may not reach the intended recipients -- the providers who
need the drug information for treating patients," explained Janet Woodcock, MD,
deputy commissioner for Scientific and Medical Programs, CMO, and acting
director Center for Drug Evaluation and Research U.S. FDA. "Gatekeepers often
discard these important paper-based alerts as 'junk mail.' We applaud the
efforts of Dr. Dickey and her board to improve the delivery of important patient
safety alerts to U. S. physicians."
"Rapid delivery of drug safety information is critical in order for us to
provide high quality care to our patients based on the latest data," said Jack
Lewin, MD, chief executive officer of the American College of Cardiology (ACC).
"We are confident that cardiologists will enroll and immediately appreciate the
benefits of the HCNN. By taking advantage of this network, we can streamline
care and save costs."
Manufacturers, led by Johnson & Johnson and the pharmaceutical industry group
PhRMA, have lent their support and leadership to the HCNN, which is devoted
exclusively to communicating urgent patient safety alerts to physicians -- it
includes no advertising. The HCNN is funded by manufacturers that use the new
online network and currently pay for U.S. mail delivery of paper-based alerts.
"As part of our longstanding commitment to product and patient safety, Johnson &
Johnson is proud to be a founding member of the Health Care Notification
Network," said Adrian Thomas, MD, chief safety officer and global head Benefit
Risk Management, Johnson & Johnson. "We believe this system will provide a
timely, effective and efficient system to distribute important medical safety
information to America's physicians."
"The entire pharmaceutical industry is united behind a commitment to patient
safety and improved speed and efficacy in delivery of alerts to U.S.
physicians," added Alan Goldhammer, PhD, associate vice president, Regulatory
Affairs for PhRMA.
Also joining the HCNN effort is the America's Health Insurance Plans (AHIP)
trade group, as well as numerous health plans including Aetna and Health Care
Service Corporation (HCSC), the parent company of Blue Cross Blue Shield of
Texas, Illinois, Oklahoma and New Mexico.
"Making health care safer is critically important to improving the quality of
life for patients. Success will depend on collaborative partnerships such as the
HCNN and leveraging technology to deliver information in ways that enable
doctors to take more timely actions," said Troyen Brennan, MD, Aetna's chief
medical officer. "Aetna is pleased to support this effort and our ongoing focus
on patient safety by encouraging participating physicians to enroll."
"Improved patient safety and reduced drug risk impacts health, costs and quality
of care," explained Paul Handel, MD, chief medical officer of HCSC. "We are
aggressively reaching out to our physicians to encourage their enrollment in the
HCNN."
Registration for U.S. physicians is available immediately at www.hcnn.net, and
tens of thousands of physicians have already enrolled as a result of recent
outreach efforts from liability carriers.
4/01/08
Source
U.S. Food and Drug Administration (FDA). Drug Alerts Sent Instantly to U.S.
Doctors via Email on New National Network. Press Release. March 25 2008.
http://www.hivandhepatitis.com/recent/2008/040108_d.html

Doctors link 'heroin days' to Hepatitis C

2008-08-25 21:44:00

Doctors link 'heroin days' to Hepatitis C
By Gaynor Dumat-ol Daleno
Pacific Daily News
gdumat-ol@...
The heroin problem on Guam between the late 1970s and early 1980s still
haunts some island families today.
Needle-sharing associated with the use of heroin helped spread Hepatitis C
on island, and complications of the disease have led to "the premature deaths of
too many Guamanians," according to flyers that some Guam doctors are circulating
to try to raise awareness of the problem.
"If you shared a needle 30 or 40 years ago, you could be infected with a deadly
disease and not even know it," according to the flyers, which are being
circulated islandwide. Complications from Hepatitis C can lead to cancer of the
liver and other liver-related health problems, said Dr. Chris Perez, one of the
doctors participating in the awareness campaign.
"All you need (to get infected) is one needle," Perez said.
"You may have (Hepatitis C) for years and not know," he added.
Part of the information drive's goal, Perez said, is to encourage those with a
heroin past, no matter how briefly it might have happened, to bring up that
piece of history with their doctors.
Doctors who are made aware of heroin use can then order tests for Hepatitis C.
"What we want to put out to the community is for the stigma to be erased," Perez
said.
For those who had used heroin, Perez said telling their doctor in confidence
could be a life-saving move.
"For the sake your life, do not be embarrassed to death -- literally," Perez
said.
Hepatitis C is treatable in certain cases that are detected and treated at an
early stage, but there are also strains that don't respond to treatment, he
said.
When heroin use was a big problem on Guam, Perez said users might have been in
the late teens to early 30s.
Sharing needles is the most common way to get infected with Hepatitis C, Perez
said.
Some people also get infected through blood transfusions, but since the
mid-1980s, the quality of blood transfusions has been highly regulated to ensure
people receive clean blood, Perez said.
On rare occasions, a person can be infected with Hepatitis C by being intimate
with another individual, but only when there's blood involved, he said.
"If you or someone you know has ever shared a needle or has ever been at risk
for exchanging bodily fluids with someone who may be infected with Hepatitis C,
you are advised to be tested, or to encourage your friend or loved one to be
tested," the flyer said.
To get tested, see your primary care doctor, it states.
"Doing so now is your best choice and will increase your chances of surviving or
managing this silent epidemic. You owe it to yourself and your loved ones," the
flyer states.
No hard number was available yesterday on former heroin users who have Hepatitis
C on Guam.
But certain island doctors are seeing enough correlation between heroin use and
Hepatitis C patients on Guam that's become a cause for concern, Perez said.
The late 1970s and the early 1980s were known as the "heroin days" on Guam.
http://www.guampdn.com/apps/pbcs.dll/article?AID=/20080331/NEWS01/803310302/1002

Re: from hepcingles.com

2008-08-25 20:43:59

I will not, I am just one person and he probably has saved many lives in his
time!! I did file a complaint. I say a little prayer for him and hand it over to
God! you are not God and neither am I!!! evil begets evil!! I would not stoop to
his level, I just take my biz somewhere else, he obviously is not educated about
HepC and is over worked at low-income clinic., but there are doctors who are
educated about this awful disease!!! this just shows how much it has been pushed
under the rug and kept silent. Remember how HIV was at first!! HepC is now being
brought into main stream media since it has spilled over into the general
population. Everyone is impacted, families, public ect.. innocent people whom
never have lived a risque life style. Be careful about choices that can have
long term consequences!!! I do thankyou for your compassion, understanding and
motivation as the answer is education, to a better life. Please use the emotions
stirred in you to do good works!!!
Peace!!
Alphone Capone <capone2065@...
of the doctor who
treated you horriable and his address. I think his
life needs to be made miserable and I can do that.
Thanks.
Respectfully,
Angelo
capone2065@...

Live near Billings Montana?

2008-08-25 16:14:57

Letter: Hepatitis C outbreaks an alarming trend
I would like to see an article done on hepatitis C, especially in light of all
the outbreaks of this horrible disease in New York and Las Vegas, just to name a
few. And now it is reaching a little closer to home, with two Indian Health
Service clinics finding the hepatitis C infection rate six times higher than in
the general population.
In Montana alone, there are about 9,000 people known to have hep C and another
5,000 who don't know they are infected. Those are just the facts for Montana!
I have hep C. I have done treatment to hopefully keep this in remission. I have
started a support group for Billings. It is the Big Sky Country Hep C support
group, with meetings at the health center in the Billings Clinic on the first
and third Wednesdays of the month, from 7 to 8 p.m. Please come in and see me.
We can help with support, information and more.
Please help raise awareness of hepatitis C. You never know: You might be the
next one infected.
Denise Hughes
Park City
http://www.billingsgazette.net/articles/2008/03/30/opinion/letters/25-hepc.txt

AFP Tumor Markers

2008-08-25 10:48:26

AFP Tumor Markers
The Test

Have Hep C and you're still drinking? A new group just for you.

2008-08-24 20:44:00

I know that many of you are still dealing with some form of addiction as
well as continuing drinking despite having Hepatitis. There is a new group at

Live near Tampa? Help Support LifeLink

2008-08-24 20:43:36

Live near Tampa?
A free park concert featuring the world renowned Florida Orchestra. This annual
event helps spread the word about the desperate need for organ donors and
celebrates the miracle of organ transplantation.
Net proceeds benefit the
LifeLink Legacy FundSM
Good Samaritan Patient Care
Programs - helping patients who,
without our support, might die.
Saturday, April 26, 2008
Al Lopez Park
7:30 PM
http://asymphonyoflife.org/

Local recipients tout transplants

2008-08-24 15:29:51

Local recipients tout transplants
Two became friends after undergoing life-saving liver procedures.
By TERESA McMINN
Between changes in his insurance provider and a lack of local resources
available to help with life-and-death decisions, Jerry Gross' future seemed
bleak.
Because of a genetic condition, he had spent years needing a liver transplant.
But then a co-worker told him about a relative who received a liver transplant
at the Mayo Clinic in Florida.
That information would eventually help save Gross' life.
Gross, 60, a York Township resident and a Vietnam veteran, said he was diagnosed
some time ago with primary sclerosing cholangitis -- a chronic, progressive
disease of the bile ducts.
He said he inherited the condition from his father, who died from liver and
stomach cancer. Gross said he suspects his paternal grandfather suffered from
the same condition.
"Going through life, I thought I could deal with anything," he said. "I found
out I was wrong."
Gross said his co-workers at Johnson Controls, where he has worked for 36 years
as a machine operator, encouraged him emotionally and held fundraisers to help
with the debt brought on by his medical condition.
"They really went out of their way," he said.
At one point, a co-worker told Gross about her relative, Pat Korcuba, who
received a liver transplant at the Mayo Clinic in Jacksonville, Fla.
"We got in touch with the Mayo Clinic," he said.
The clinic evaluated Gross in April 2007.
"I finally got on the list on May 17," he said.
Gross and his wife, Cathy, a phlebotomist at York Hospital, moved to Florida.
Soon after, Jerry Gross received a liver transplant.
"By June 3 (2007), I got the transplant," he said. "I was back to work within
three-and-a-half months of the transplant. I would have died up here. The Mayo
Clinic is an incredible place."
After the transplant operation, the couple moved back to York Township.
Gross said he takes anti-rejection medication and feels well.
Gross and Korcuba said their goal is to make people aware of the transplant
program at the Mayo Clinic.
Korcuba, a York Township resident who received a liver transplant at Mayo Clinic
in 2005, said the Florida clinic saved her life.
"They have such a great donor program down there," she said. "They really
promote organ donation. They are just wonderful."
THE CLINIC
Megan Vandekerckhove, a spokeswoman for the Mayo Clinic in Jacksonville, Fla.,
said the center performs solid organ and bone marrow transplants.
She said the clinic performed 10 liver transplant surgeries this month, 45 so
far this year and 1,724 since 1998.
For more information, visit www.mayoclinic.org/jacksonville.
http://ydr.inyork.com/ci_8723489

Transplants can be financial burden

2008-08-24 08:04:39

Transplants can be financial burden
By TERESA McMINN
For the Daily Record/Sunday News
Article Last Updated: 03/28/2008 01:31:19 AM EDT
When a loved one is in need of a liver transplant, family members can become
emotionally drained.
In many cases, they also may face heavy financial burdens.
Linda Amos-Ganther of West York knows how devastating liver cancer can be. Her
husband, George Ganther, 49, was diagnosed in 2006 with inoperable liver cancer.
On Sept. 14, 2007, he received a liver transplant at Penn State Milton S.
Hershey Medical Center, the day after his wife's birthday.
"It was the best gift that God could have ever given me," Linda Amos-Ganther
said.
However, the family did face mounting medical bills.
"I call him the $1.2 million man," Amos-Ganther said of her husband. His first
post-surgery anti-rejection pill cost more than $3,000, she said.
"George will be on anti-rejection medication for the rest of his life," Linda
Amos-Ganther said.
The couple used insurance policies, money from savings, checking accounts and
trusts and sold bank shares to help pay down the debt.
"You almost have to be an accountant, medical person and nurse," Linda said. "I
had to question everything. It's sad because people who are meek and quiet are
just going to get lost in the process."
She also said a New Cumberland organization, Vickie's Angel Walk, provided help
to the couple.
"When nobody else would help us financially, they helped us," she said. "They
made the difference between us having groceries and us not having groceries."
When Vickie Minnich died from cancer in 2003, her husband, Mickey, and her two
sons founded the non-profit organization Vickie's Angel Walk. The group helps
provide financial assistance for families fighting cancer.
"In five years we've raised over $250,000," Mickey Minnich said. "We're unique.
We don't set a limit on the family."
ORGAN DONATION
April is National Donate Life Month. Facts about organ donation:
--- More than 95,000 people need an organ transplant.
--- About 77 people per day get an organ transplant, but 17 to 19 others die
because they didn't receive an organ transplant.
--- Chances of getting a transplant increase if the donor and the recipient
share the same ethnic background.
Source: www.organdonor.gov
ON THE WEB
To learn more about Vickie's Angel Walk, visit www.vickiesangelwalk.org .
http://ydr.inyork.com/ci_8722951

For big surgery, Delhi is dealing

2008-08-24 03:30:59

For big surgery, Delhi is dealing
Medical tourism soars as Americans seek major savings on health care in
hospitals abroad
By Laurie Goering | Tribune correspondent
1:33 AM CDT, March 28, 2008
NEW DELHI - When James Payne found out he needed a liver transplant, he first
tried to arrange the surgery at a top local hospital in South Florida. Doctors
there told him that they couldn't schedule the procedure for a few months and
that it would cost $450,000, a fortune for the uninsured former investment
banker.
So the 55-year-old and his wife, who planned to donate half her own liver to her
husband, bought plane tickets to India instead. There, at one of New Delhi's
premier hospitals, a transplant specialist did the surgery for $58,000-a price
tag that included their 10-week hospital stay.
"If you want to live, this is where you come," said a smiling Payne, who planned
to return home to Florida this week and said he would recommend his experience
to anyone suffering similar problems.
The number of Americans heading abroad for medical procedures is surging as the
country's 46 million people without health insurance look for treatment they can
afford and cash-strapped U.S. companies struggle to find cheaper ways to provide
high-quality medical care to their employees, according to the American Medical
Association.
Mexico has long attracted American travelers looking for cut-rate cosmetic
surgery or dental work, and countries like Malaysia, Thailand and the
Philippines continue to lure medical tourists as well.
But India-15 hours away from the U.S. by plane-is fast becoming the destination
of choice for patients seeking complicated high-end procedures they can't afford
or can't manage to schedule with a doctor they trust at home. These include
things like heart surgery, organ transplants and orthopedic procedures like knee
replacement or hip resurfacing.
150,000 medical tourists
Last year, the South Asian giant attracted 150,000 medical tourists from the
United States, Britain, Africa and elsewhere in South Asia, largely by offering
an enticing trio of advantages: highly trained English-speaking doctors, quick
appointments and bargain-basement prices. In India, a heart bypass goes for
$10,000 and a hip replacement for $9,000, compared with $130,000 and $43,000
respectively in the United States, the AMA said.
India's initial rush of patients, however, may be nothing compared with what is
to come. According to the AMA, major U.S. employers and insurers are exploring
whether they could hold down soaring health-care costs by shipping their workers
halfway across the world for elective surgery.
"Major [insurers] and employers may soon follow in the footsteps of
individuals," the medical association said in a report released last June. It
acknowledged that "prices offered to medical tourists are often 60 to 85 percent
lower than insurer-negotiated charges in the U.S., a margin that easily offsets
travel, first-class hotel for the patient" and other expenses.
Several Fortune 500 companies and the West Virginia Legislature are among those
considering bonuses - including first-class airfare and four-star hotel
stays-for employees willing to undergo medical treatment abroad. And several
major insurers already cover treatment programs in Mexico and Thailand, the AMA
said.
Traveling to India for medical care is not without its problems, of course. The
country may be increasingly known for its well-educated workers, high-tech call
centers and new wealth, but squalor and chaos are still regular features of
life.
Malpractice laws are weaker, leaving patients who run into problems while being
treated with little legal recourse. Patients may struggle to find U.S. doctors
willing to take on after-surgery care once they return home. And the flight to
India may be difficult-even in business class -for anyone with a serious medical
problem.
But India is working hard to make traveling for surgery as appealing as possible
for foreigners. The country recently created a special medical visa
classification for tourists seeking health care. Some top-of-the-line hospitals
and hotels are teaming up to build joint facilities. And many hospitals and
medical tourism sales firms offer package deals-from airport pickup to
t